Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | RHOC | P08134 | 1/20 | 0.33 |
| ▸ | RHOA | P61586 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16099794 | 0.87 | BTK (0.35) | BTKFABP4MC4RCXCR3RHOA | |
| SCHEMBL16100249 | 0.82 | MEN1 (0.37) | NPC1SMN1; SMN2 | |
| SCHEMBL16099914 | 0.82 | ENPP2 (0.41) | LMNAGAASMN1; SMN2 | |
| SCHEMBL16129778 | 0.80 | TACR1 (0.38) | NPC1 | |
| SCHEMBL16099623 | 0.80 | TACR1 (0.39) | — | |
| SCHEMBL16094524 | 0.76 | TACR1 (0.34) | — | |
| SCHEMBL16093646 | 0.75 | ENPP2 (0.40) | GRM5 | |
| SCHEMBL16094523 | 0.74 | TACR1 (0.40) | — | |
| SCHEMBL16093608 | 0.74 | ENPP2 (0.44) | — | |
| SCHEMBL16094214 | 0.74 | ENPP2 (0.42) | RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | claimed |
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN MA INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2970302-A1 | S1P AND/OR ATX MODULATING AGENTS | Biogen MA Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152725-A1 | S1P AND/OR ATX MODULATING AGENTS | BIOGEN IDEC MA INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039825-A1 | S1P AND/OR ATX MODULATING AGENTS | ENPP2, S1PR1, S1PR2 | BTK 3491/4885FABP4 3980/4885EGLN1 2253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.